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A homozygous deletion of exon 1 inWISP3 causes progressive
pseudorheumatoid dysplasia in two siblings
Barbara Neerinckx1,2, Cedric Thues3, Carine Wouters4, Sarah Lechner5, Rene Westhovens1,2 and Hilde Van Esch3
Progressive pseudorheumatoid dysplasia (PPD) is a rare autosomal recessive disease that causes progressive joint stiffness and pain.
It is associated with loss-of-function mutations in the WISP3 gene. We describe two sisters suffering from PPD in whom molecular
genetic analysis revealed a homozygous deletion of exon 1 and of the 5′UTR of the WISP3 gene. This is the first time that a gross
deletion has been described as the causal mutation in PPD.
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PPD is a rare autosomal recessive disease characterised by
progressive joint stiffness, motor weakness, gait disturbances,
articular pain and contractures.1,2 This non-inflammatory
arthropathy was first described by Wynne-Davies et al.4 and
independently by Spranger et al.3 Classically, the disease presents
with decreased joint mobility, in particular reduced hip
movements, and a progressive involvement of metacarpophalan-
geal joints, proximal interphalangeal joints, distal interphalangeal
joints, wrists, elbows, knees, shoulders and ankles.1,3,4 In most
cases, principal disability arises from hip involvement resulting in
pain, limitation of movements and contractures.4 In addition to
the hip, hand involvement is one of the most frequent and typical
features of PPD.2 The initial symptoms of the disease manifest
primarily in childhood, between 3 and 8 years of age.2,4 All
patients previously described were normal at birth2–4 and did not
have any other dysmorphic characteristics.4 There are no
extra-skeletal manifestations of the disease. The stature of patients
with PPD is normal in infancy, but deviates generally to lower than
the third percentile in adulthood.2 PPD is a progressive disease,
although the rate of progression varies between patients.1 The
population incidence of PPD is estimated to be ~ 1 in a million
in the United Kingdom,4 but it appears to be higher in the
Middle-East and Gulf States as well as in Turkey, where a founder
effect has been suggested.2,5
Radiographs from patients with PPD have some typical features.
Radiographs from the hip show a large capital femoral epiphysis,
a short femoral neck and a decreased intra-articular space
(Figure 1).1,2,4 The hands show enlarged epiphyses and meta-
physes of the metacarpals and proximal and middle phalanges,
often mistaken as ‘joint swelling’, and periarticular osteoporosis
(Figure 1).1,2,4 Periarticular osteoporosis can also be present at
other joints. Another typical feature is vertebral flattening or
platyspondyly (Figure 1).1,4,6 PPD never presents with erosions,
periostitis or joint destructions.1,4
Most patients are initially misdiagnosed because of the rarity of
the disease and the lack of awareness of most clinicians. The
presentation of PPD can mimic juvenile idiopathic arthritis1,3,4 as
osseous joint swelling can be mistaken for synovitis; although
there is no evidence of inflammation in PPD as inflammatory
markers (such as ESR and CRP) are always within the normal range.
Radiographs can also help to distinguish between these two
diseases as destructive or erosive bone changes are never seen on
radiographs from PPD patients.1,3,4
As there is no active inflammation, the response to the
conventional anti-rheumatic treatment with disease-modifying
antirheumatic drugs and nonsteroidal anti-inflammatory drugs is
disappointing.1,4 The exact pathomechanism is still unclear;
consequently, no specific treatment is currently available.2 Hip
replacement may be useful in some cases. There are no
longitudinal studies, but patients who underwent hip replacement
seem to suffer from less pain and regain walking ability.2
In 1999, loss-of-function mutations in the WISP3 gene were
identified as being responsible for PPD.6 Here, we describe two
sisters suffering from PPD in whom molecular genetic analysis
showed a homozygous deletion of exon 1 and of the 5′UTR of the
WISP3 gene. To the best of our knowledge, this is the first time
that a gross deletion has been detected as the causal mutation
in PPD.
The first patient is a currently 27-year-old woman of Moroccan
origin who presented for the first time in our hospital at the age of
7 because of articular pain and short stature. A normal pregnancy
was reported, and no abnormalities were noted as a baby. At birth,
her length was at the 50th percentile. From the age of 18 months,
her length curve dropped to the third percentile and was even
lower from the age of 3 years on. At the age of 4, she underwent a
bilateral valgisation osteotomy of the tibia because of Blount’s
syndrome. Physical examination at that time showed short stature,
just below the third percentile, and bilateral prominent genu
valgum with an impaired gait and thickening of the small finger
joints with restricted flexion and extension. Laboratory tests were
normal without signs of inflammation. Radiographs showed global
osteopenia, ovoid vertebrae and widened distal epiphyses from
the metacarpal bones, the proximal phalanges and the distal
phalanges (Figure 1a). The diagnosis of PPD was made, and the
patient began intensive physiotherapy. She underwent a total hip
replacement surgery of the left side at the age of 18 and of the
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right side at the age of 19, with a satisfactory outcome. Physical
examination currently shows a body height of 132 cm, an
impaired gait, fixed flexion of hips and knees, impossible
dorsiflexion of the wrists and bony thickening of the interpha-
langeal joints with functional limitations. Despite these physical
limitations, she functions quite well in daily life and has almost no
need for painkillers.
The second patient is the sister of the first patient who is 3 years
younger. She first presented in our centre at the age of 7 because
of articular pain in the legs. Physical examination showed a normal
length and weight, a slightly impaired gait, bony thickening of the
interphalangeal joints, incomplete extension of the knees,
impaired flexion, abduction and internal rotation of the hips and
limited flexion of the cervical spine. Radiographs show widened
epiphyses of the phalanges (Figure 1a). Because her sister was
diagnosed a couple of years before with PPD, the diagnosis was
obvious, although she exhibited a milder clinical presentation. At
present, physical examination shows finger deformations; slightly
limited motion of the shoulders, elbows, wrists and hips; and
cervical impairment. She does not take any drugs and is well
adapted to daily life.
Their parents, as well as their two older brothers, are healthy
and do not suffer from the disease. There is no known
consanguinity between the parents, but they both originated
from the same village. Both sisters asked for genetic counselling
and all individuals involved gave written informed consent
according to the Helsinki declaration.
DNA extracted from peripheral white blood cells was obtained
from both affected siblings and parents according to standard
procedures. Molecular mutation analysis was performed and
resulted in a repeated failure to amplify the first exon using the
traditional PCR method. Using quantitative real-time PCR, as
previously described,6 a homozygous deletion of the 5′UTR and
the first exon of the WISP3 gene was detected (Figure 1b). We
designed additional primers (Figures 1c and d; sequences
available on request) and were able to delineate the deletion to
a maximum of 9 kb extending into the 5′UTR. Parents are both
heterozygous carriers of the deletion (Figure 1b). No mutation
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Figure 1. (a) Radiographs of the hips of patient 1 (1) and patient 2 (2). Both radiographs show large capital femoral epiphysis, a short femoral
neck and a decreased intra-articular space. Radiographs of the lumbar spine of patient 1 show platyspondyly (3–4). Radiographs of the hand
of patient 2 (5) showing widened epiphyses and metaphyses of the metacarpals and proximal and middle phalanges. (b) qPCR data using
primer sets 4 (blue) and 5 (red) on genomic DNA from all family members. The values for the fold differences compared with controls are
shown on the y-axis. C1 control 1; C2 control 2; F father; M mother; P1 patient 1; P2 patient 2. (c) Gel image of the PCR analysis with primer sets
1, 2, 3 and 6 on control and patient DNA showing that no product could be obtained for primer sets 3 and 6 that map within the homozygous
deletion. The first lane is the 100 bp DNA ladder. PCR products are all ~ 500 bp in size. (d) The WISP3 gene, located on chromosome 6q21,
consists of five coding exons (boxes, ATG start codon in exon 1). Molecular analysis of WISP3 by quantitative real-time PCR revealed a
homozygous deletion of the 5′UTR and the first exon of the WISP3 gene (qPCR primer sets are depicted as arrows) with a maximal deleted
region of 9 kb (box).
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was detected in the amplified and sequenced exons 2–5 of the
WISP3 gene.
In 1999, Hurvitz et al.7 showed for the first time an association
between PPD and mutations in the CCN (for CTGF, cyr61/cef10,
nov) family member WISP3 by using a positional-candidate
approach. The CCN family encodes cysteine-rich secreted growth
factors that regulate cell proliferation, differentiation, migration
and adhesion. The high conservation of cysteines in the CNN
proteins suggests that these residues are essential for their
function.2,7 To date, more than 20 mutations in the WISP3 gene
have been published. All of these mutations are loss-of-function
mutations, including deletions, frame shifts and missense
mutations.2 There is a large molecular spectrum of mutations, as
mutations have been identified in all protein domains of WISP3,
and no clear genotype–phenotype correlation has been
established.2
Currently, little is known about the biological activity of WISP3.
The level of expression of WISP3 is rather low.7 The transcript is
detected mainly in mesenchymal cells and tissues such as
chondrocytes, synoviocytes and bone marrow progenitor cells
induced to undergo in vitro chondrogenesis.2,7 WISP3 appears to
play a role in the expression of collagen type II, aggrecan and
SOX9, which explains why PPD is characterised by an arthropathy
primarily affecting the articular cartilage.8 It appears that WISP3 is
a potential stimulator of anabolic pathways in cartilage. Because
WISP3 depletion or overexpression fails to show a pathological
phenotype in mice,9 zebrafish were used for further in vivo
research. Overexpression of WISP3 in zebrafish led to the
inhibition of BMP and WNT signalling, whereas depletion of
WISP3 led to no or decreased inhibition of these pathways.10
Therefore, the dysregulation of BMP and/or WNT signalling may
contribute to cartilage failure in PPD patients.
The mutation in the WISP3 gene was confirmed in our two
patients. A homozygous deletion of the 5′UTR and the first coding
exon of the WISP3 gene was detected. To the best of our
knowledge, no large deletions in the WISP3 gene have been
described previously. The deletion of the 5′ region will most likely
prevent mRNA transcription and will therefore result in WISP3
insufficiency. The detection of the mutation in both sisters
confirms the diagnosis of PPD and shows that both parents are
most likely distant relatives.
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The relevant data from this Data Report are hosted at the Human
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